Assessment of Established Techniques to Determine Developmental and Malignant 
Potential of Human Pluripotent Stem Cells

Allison, Thomas F.; Andrews, Peter W.; Avior, Yishai; Barbaric, Ivana; Benvenisty, Nissim; Bock, Christoph; Brehm, Jennifer; Bruestle, Oliver; Damjanov, Ivan; Elefanty, Andrew; Felkner, Daniel; Gokhale, Paul J.; Halbritter, Florian; Healy, Lyn E.; Hu, Tim X.; Knowles, Barbara B.; Loring, Jeanne F.; Ludwig, Tenneille E.; Mayberry, Robyn; Micallef, Suzanne; Mohamed, Jameelah S.; Müller, Franz-Josef; Mummery, Christine L.; Nakatsuji, Norio; Ng, Elizabeth S.; Oh, Steve K. W.; O'Shea, Orla; Pera, Martin F.; Reubinoff, Benjamin; Robson, Paul; Rossant, Janet; Schuldt, Bernhard M.; Solter, Davor; Sourris, Koula; Stacey, Glyn; Stanley, Edouard G.; Suemori, Hirofumi; Takahashi, Kazutoshi; Yamanaka, Shinya

doi:10.1038/s41467-018-04011-3

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

Assessment of Established Techniques to Determine Developmental and Malignant Potential of Human Pluripotent Stem Cells

MPS-Authors

/persons/resource/persons220217

Müller, Franz-Josef
Cellular Phenotyping (Franz-Josef Müller), Dept. of Genome Regulation, (Head: Alexander Meissner), Max Planck Institute for Molecular Genetics, Max Planck Society;

External Resource

No external resources are shared

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

Allison.pdf
(Publisher version), 3MB

Supplementary Material (public)

There is no public supplementary material available

Citation

Allison, T. F., Andrews, P. W., Avior, Y., Barbaric, I., Benvenisty, N., Bock, C., et al. (2018). Assessment of Established Techniques to Determine Developmental and Malignant Potential of Human Pluripotent Stem Cells. Nature Communications, 9(1): 1925. doi:10.1038/s41467-018-04011-3.

Cite as: https://hdl.handle.net/21.11116/0000-0003-8DDD-6

Abstract

The International Stem Cell Initiative compared several commonly used approaches to assess human pluripotent stem cells (PSC). PluriTest predicts pluripotency through bioinformatic analysis of the transcriptomes of undifferentiated cells, whereas, embryoid body (EB) formation in vitro and teratoma formation in vivo provide direct tests of differentiation. Here we report that EB assays, analyzed after differentiation under neutral conditions and under conditions promoting differentiation to ectoderm, mesoderm, or endoderm lineages, are sufficient to assess the differentiation potential of PSCs. However, teratoma analysis by histologic examination and by TeratoScore, which estimates differential gene expression in each tumor, not only measures differentiation but also allows insight into a PSC's malignant potential. Each of the assays can be used to predict pluripotent differentiation potential but, at this stage of assay development, only the teratoma assay provides an assessment of pluripotency and malignant potential, which are both relevant to the pre-clinical safety assessment of PSCs.